Irritable Bowel Syndrome (IBS) Questions & Answers

1. Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease?. Gastroenterol Clin North Am. 2005 Jun. 34(2):235-45, vi-vii. [QxMD MEDLINE Link].

2. Schmulson MJ, Drossman DA. What is new in Rome IV. J Neurogastroenterol Motil. 2017 Apr 30. 23(2):151-63. [QxMD MEDLINE Link]. [Full Text].

3. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al, for the American College of Gastroenterology Task Force on Irritable Bowel Syndrome. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009 Jan. 104 suppl 1:S1-35. [QxMD MEDLINE Link].

4. National Center for Complementary and Integrative Health. September, 2016. Peppermint oil. Available at https://nccih.nih.gov/health/peppermintoil. Accessed: April 2, 2019.

5. Trulance (plecanatide) [package insert]. New York, NY: Synergy Pharmaceuticals Inc. January, 2018. Available at [Full Text].

6. Chey WD, Lembo AJ, Yan A, Rosenbaum DP. Efficacy and safety of tenapanor in patients with constipation predominant irritable bowel syndrome: a 6-month, double-blind, placebo-controlled phase 3 trial (T3MPO-2) [abstract 885]. Presented at: Digestive Disease Week; June 2-5, 2018; Washington, DC. Gastroenterology. 2018 May. 54(6 suppl 1):S-1362. [Full Text].

7. Spiegel BM, Farid M, Esrailian E, Talley J, Chang L. Is irritable bowel syndrome a diagnosis of exclusion? A survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol. 2010 Apr. 105(4):848-58. [QxMD MEDLINE Link]. [Full Text].

8. Chumpitazi BP, Shulman RJ. Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome. Mol Cell Pediatr. 2016 Dec. 3(1):11. [QxMD MEDLINE Link]. [Full Text].

9. Quigley EMM. The gut-brain axis and the microbiome: clues to pathophysiology and opportunities for novel management strategies in irritable bowel syndrome (IBS). J Clin Med. 2018 Jan 3. 7(1):6. [QxMD MEDLINE Link]. [Full Text].

10. Farzaei MH, Bahramsoltani R, Abdollahi M, Rahimi R. The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. J Neurogastroenterol Motil. 2016 Oct 30. 22(4):558-74. [QxMD MEDLINE Link]. [Full Text].

11. Miller V, Hopkins L, Whorwell PJ. Suicidal ideation in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2004 Dec. 2(12):1064-8. [QxMD MEDLINE Link].

12. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009 May. 136(6):1979-88. [QxMD MEDLINE Link].

13. Tornblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology. 2002 Dec. 123(6):1972-9. [QxMD MEDLINE Link].

14. Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007 Jul. 133(1):24-33. [QxMD MEDLINE Link].

15. Camilleri M. Functional gastrointestinal disorders: novel insights and treatments. Medscape General Medicine. 1999. Available at http://www.medscape.com/viewarticle/717346. Accessed: September 20, 2010.

16. Wensaas KA, Langeland N, Hanevik K, Morch K, Eide GE, Rortveit G. Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: historic cohort study. Gut. 2012 Feb. 61(2):214-9. [QxMD MEDLINE Link].

17. Lacy BE. The science, evidence, and practice of dietary interventions in irritable bowel syndrome. Clin Gastroenterol Hepatol. 2015 Nov. 13(11):1899-906. [QxMD MEDLINE Link].

18. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003 Feb. 98(2):412-9. [QxMD MEDLINE Link].

19. Quigley EMM. Are diets the answers to colon ills? Food, irritable bowel syndrome and the microbiome. Curr Opin Gastroenterol. 2018 Mar. 34(2):103-4. [QxMD MEDLINE Link].

20. Shepherd SJ, Parker FC, Muir JG, Gibson PR. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol. 2008 Jul. 6(7):765-71. [QxMD MEDLINE Link].

21. Chumpitazi BP, McMeans AR, Vaughan A, et al. Fructans exacerbate symptoms in a subset of children with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2018 Feb. 16(2):219-25.e1. [QxMD MEDLINE Link]. [Full Text].

22. Henstrom M, Diekmann L, Bonfiglio F, et al. Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. Gut. 2018 Feb. 67(2):263-70. [QxMD MEDLINE Link]. [Full Text].

23. Garcia-Etxebarria K, Zheng T, Bonfiglio F, et al. Increased prevalence of rare sucrase-isomaltase (SI) pathogenic variants in irritable bowel syndrome patients. Clin Gastroenterol Hepatol. 2018 Oct. 16(10):1673-6. [QxMD MEDLINE Link]. [Full Text].

24. Knowles SR, Austin DW, Sivanesan S, et al. Relations between symptom severity, illness perceptions, visceral sensitivity, coping strategies and well-being in irritable bowel syndrome guided by the common sense model of illness. Psychol Health Med. 2017 Jun. 22(5):524-34. [QxMD MEDLINE Link].

25. Palsson OS, van Tilburg MA, Simren M, Sperber AD, Whitehead WE. Population prevalence of Rome IV and Rome III irritable bowel syndrome (IBS) in the United States (US), Canada and the United Kingdom (UK) [abstract Mo1642]. Gastroenterology. Apr 2016. 150(4 suppl 1):S739-40. [Full Text].

26. Khashan AS, Quigley EM, McNamee R, McCarthy FP, Shanahan F, Kenny LC. Increased risk of miscarriage and ectopic pregnancy among women with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2012 Aug. 10(8):902-9. [QxMD MEDLINE Link].

27. Silvernale C, Kuo B, Staller K. Lower socioeconomic status is associated with an increased prevalence of comorbid anxiety and depression among patients with irritable bowel syndrome: results from a multicenter cohort. Scand J Gastroenterol. 2019 Sep. 54(9):1070-4. [QxMD MEDLINE Link].

28. Han CJ, Pike K, Jarrett ME, Heitkemper MM. Symptom-based latent classes of persons with irritable bowel syndrome. Res Nurs Health. 2019 Oct. 42(5):382-91. [QxMD MEDLINE Link].

29. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J. 1978 Sep 2. 2(6138):653-4. [QxMD MEDLINE Link]. [Full Text].

30. Sood R, Camilleri M, Gracie DJ, et al. Enhancing diagnostic performance of symptom-based criteria for irritable bowel syndrome by additional history and limited diagnostic evaluation. Am J Gastroenterol. 2016 Oct. 111(10):1446-54. [QxMD MEDLINE Link].

31. Almazar AE, Talley NJ, Larson JJ, Atkinson EJ, Murray JA, Saito YA. Celiac disease is uncommon in irritable bowel syndrome in the USA. Eur J Gastroenterol Hepatol. 2018 Feb. 30(2):149-54. [QxMD MEDLINE Link]. [Full Text].

32. Ford AC, Moayyedi P, Lacy BE, et al, for the Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014 Aug. 109 suppl 1:S2-26; quiz S27. [QxMD MEDLINE Link].

33. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011 Aug 10. 2011(8):CD003460. [QxMD MEDLINE Link]. [Full Text].

34. Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol. 2011 Mar. 106(3):508-14; quiz 515. [QxMD MEDLINE Link].

35. Volta U, Pinto-Sanchez MI, Boschetti E, Caio G, De Giorgio R, Verdu EF. Dietary triggers in irritable bowel syndrome: is there a role for gluten?. J Neurogastroenterol Motil. 2016 Oct 30. 22(4):547-57. [QxMD MEDLINE Link]. [Full Text].

36. Gibson PR, Varney J, Malakar S, Muir JG. Food components and irritable bowel syndrome. Gastroenterology. 2015 May. 148(6):1158-74.e4. [QxMD MEDLINE Link].

37. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014 Jan. 146(1):67-75.e5. [QxMD MEDLINE Link].

38. Valeur J, Smastuen MC, Knudsen T, Lied GA, Roseth AG. Exploring gut microbiota composition as an indicator of clinical response to dietary FODMAP restriction in patients with irritable bowel syndrome. Dig Dis Sci. 2018 Feb. 63(2):429-36. [QxMD MEDLINE Link].

39. Tuck CJ, Caminero A, Jimenez Vargas NN, et al. The impact of dietary fermentable carbohydrates on a postinflammatory model of irritable bowel syndrome. Neurogastroenterol Motil. 2019 Oct. 31(10):e13675. [QxMD MEDLINE Link].

40. Nawawi KNM, Belov M, Goulding C. Low FODMAP diet significantly improves IBS symptoms: an Irish retrospective cohort study. Eur J Nutr. 2019 Sep 13. [QxMD MEDLINE Link].

41. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010 Mar. 59(3):325-32. [QxMD MEDLINE Link].

42. Shanahan F, Quigley EM. Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies. Gastroenterology. 2014 May. 146(6):1554-63. [QxMD MEDLINE Link].

43. Principi N, Cozzali R, Farinelli E, Brusaferro A, Esposito S. Gut dysbiosis and irritable bowel syndrome: The potential role of probiotics. J Infect. 2018 Feb. 76(2):111-20. [QxMD MEDLINE Link].

44. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009 Apr. 104(4):1033-49; quiz 1050. [QxMD MEDLINE Link].

45. Liu HN, Wu H, Chen YZ, Chen YJ, Shen XZ, Liu TT. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis. Dig Liver Dis. 2017 Apr. 49(4):331-7. [QxMD MEDLINE Link].

46. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014 Oct. 109(10):1547-61; quiz 1546, 1562. [QxMD MEDLINE Link].

47. Cremon C, Stanghellini V, Barbaro MR, et al. Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. Aliment Pharmacol Ther. 2017 Apr. 45(7):909-22. [QxMD MEDLINE Link]. [Full Text].

48. Khayyatzadeh SS, Kazemi-Bajestani SMR, Mirmousavi SJ, et al. Dietary behaviors in relation to prevalence of irritable bowel syndrome in adolescent girls. J Gastroenterol Hepatol. 2018 Feb. 33(2):404-10. [QxMD MEDLINE Link].

49. Zijdenbos IL, de Wit NJ, van der Heijden GJ, Rubin G, Quartero AO. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst Rev. 2009 Jan 21. CD006442. [QxMD MEDLINE Link].

50. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009 Mar. 58(3):367-78. [QxMD MEDLINE Link].

51. [Guideline] Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021 Jul. 70(7):1214-40. [QxMD MEDLINE Link]. [Full Text].

52. [Guideline] Ford AC, Moayyedi P, Chey WD, et al, for the ACG Task Force on Management of Irritable Bowel Syndrome. American College of Gastroenterology monograph on management of irritable bowel syndrome. Am J Gastroenterol. 2018 Jun. 113(suppl 2):1-18. [QxMD MEDLINE Link]. [Full Text].

53. Rey E, Mearin F, Alcedo J, et al. Optimizing the use of linaclotide in patients with constipation-predominant irritable bowel syndrome: an expert consensus report. Adv Ther. 2017 Mar. 34(3):587-98. [QxMD MEDLINE Link]. [Full Text].

54. Synergy Pharmaceuticals announces FDA approval of Trulance (plecanatide) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults [press release]. Synergy Pharmaceuticals. January 25, 2018. Available at https://ir.synergypharma.com/press-releases/detail/1861/synergy-pharmaceuticals-announces-fda-approval-of. Accessed: January 25, 2018.

55. Valeant Pharmaceuticals International, Inc. Salix announces FDA approval of Xifaxan 550 mg for the treatment of IBS-D (irritable bowel syndrome with diarrhea). Cision PR Newswire. May 27, 2015. Available at https://www.prnewswire.com/news-releases/salix-announces-fda-approval-of-xifaxan-550-mg-for-the-treatment-of-ibs-d-irritable-bowel-syndrome-with-diarrhea-300089821.html. Accessed: June 6, 2015.

56. Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012 Jan. 107(1):28-35; quiz 36. [QxMD MEDLINE Link].

57. Pimentel M, Lembo A, Chey WD, et al, for the TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011 Jan 6. 364(1):22-32. [QxMD MEDLINE Link]. [Full Text].

58. Zelnorm (tegaserod) [package insert]. Louisville, KY: Sloan Pharma. March 2019. Available at [Full Text].

59. Brooks M. FDA OKs reintroduction of tegaserod (Zelnorm) for IBS-C in women under 65. Medscape Medical News. April 2, 2019. Available at http://medscape.com/viewarticle/911237. Accessed: April 2, 2019.

60. Madia VN, Messore A, Saccoliti F, et al. Tegaserod for the treatment of irritable bowel syndrome. Antiinflamm Antiallergy Agents Med Chem. 2020. 19(4):342-69. [QxMD MEDLINE Link]. [Full Text].

61. US Food and Drug Administration. FDA approves Linzess to treat certain cases of irritable bowel syndrome and constipation. August 30, 2012. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm317505.htm. Accessed: May 12, 2015.

62. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012 Nov. 107(11):1714-24; quiz p.1725. [QxMD MEDLINE Link]. [Full Text].

63. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012 Nov. 107(11):1702-12. [QxMD MEDLINE Link].

64. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006 Apr. 130(5):1480-91. [QxMD MEDLINE Link].

65. Chang L, Tong K, Ameen V. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol. 2010 Apr. 105(4):866-75. [QxMD MEDLINE Link].

66. Drossman DA, Corazziari E, Delvaux M, et al. Rome Foundation diagnostic algorithms. Appendix A: Psychosocial alarm questionnaire for the functional GI disorders. Am J Gastro. Apr 2010. 105(4): 795-7. [Full Text].

67. Vazquez-Roque MI, Camilleri M, Smyrk T, et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology. 2013 May. 144 (5):903-11.e3. [QxMD MEDLINE Link].

68. Henstrom M, D'Amato M. Genetics of irritable bowel syndrome. Mol Cell Pediatr. 2016 Dec. 3(1):7. [QxMD MEDLINE Link]. [Full Text].

69. Boersma K, Ljotsson B, Edebol-Carlman H, Schrooten M, Linton SJ, Brummer RJ. Exposure-based cognitive behavioral therapy for irritable bowel syndrome. A single-case experimental design across 13 subjects. Cogn Behav Ther. 2016 Nov. 45(6):415-30. [QxMD MEDLINE Link].

70. Blake MR, Raker JM, Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2016 Oct. 44(7):693-703. [QxMD MEDLINE Link]. [Full Text].

71. Miner PB Jr. Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome. Expert Opin Pharmacother. 2018 Feb. 19(2):177-83. [QxMD MEDLINE Link].

72. Black CJ, Ford AC, Houghton LA. Editorial: understanding differences in patient response to ondansetron in irritable bowel syndrome with diarrhoea-are we any closer?. Aliment Pharmacol Ther. 2019 Oct. 50(7):825-6. [QxMD MEDLINE Link]. [Full Text].

73. Gunn D, Garsed K, Lam C, et al. Editorial: understanding differences in patient response to ondansetron in irritable bowel syndrome with diarrhoea-are we any closer? Authors' reply. Aliment Pharmacol Ther. 2019 Oct. 50(7):826-7. [QxMD MEDLINE Link]. [Full Text].

Jenifer K Lehrer, MD Attending Physician, Department of Gastroenterology, Jefferson Health System Torresdale Campus, Philadelphia

Jenifer K Lehrer, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, American Medical Association

Disclosure: Nothing to disclose.

Gary R Lichtenstein, MD Professor of Medicine, Director, Center for Inflammatory Bowel Disease, Department of Medicine, Division of Gastroenterology, Perelman School of Medicine at the University of Pennsylvania

Gary R Lichtenstein, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Abbott Corp/Abbvie; Actavis; Alaven; CellCeutrix; Celgene; Ferring; Gilead; Hospira; Janssen Orthobiotech; Luitpold/American Regent; Pfizer Pharm; Prometheus Labs; Romark; Salix Pharma/Valeant; Santarus/Receptos/Celgene; Shire Pharma; Takeda; UCB<br/>Received research grant from: Salix Pharm/Valeant; Santarus/Receptos/Celgene; Shire Pharm; UCB<br/>Received author or editor honorarium or book royalty from for: Clinical Advances in Gastroenterology; Gastroenterology and Hepatology; Gastro-Hep Communications; Ironwood; Luitpold/American Regent; Merck; McMahon Publishing; Romark; SLACK Inc; Springer Science and Business Media; Up-To-Date.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Douglas M Heuman, MD, FACP, FACG, AGAF Chief of GI, Hepatology, and Nutrition at North Shore University Hospital/Long Island Jewish Medical Center; Professor, Department of Medicine, Hofstra North Shore-LIJ School of Medicine

Douglas M Heuman, MD, FACP, FACG, AGAF is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Physicians, and American Gastroenterological Association

Disclosure: Novartis Grant/research funds Other; Bayer Grant/research funds Other; Otsuka Grant/research funds None; Bristol Myers Squibb Grant/research funds Other; Scynexis None None; Salix Grant/research funds Other; MannKind Other

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Rajeev Vasudeva, MD, FACG Clinical Professor of Medicine, Consultants in Gastroenterology, University of South Carolina School of Medicine

Rajeev Vasudeva, MD, FACG is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, Columbia Medical Society, South Carolina Gastroenterology Association, and South Carolina Medical Association

Disclosure: Pricara Honoraria Speaking and teaching; UCB Consulting fee Consulting

• Print this section
• Print the entire contents of
• Print the entire contents of article